Skip to main content

Table 2 Adjusted association between quartile of reticulocyte count and mortality

From: Higher reticulocyte counts are associated with higher mortality rates in hemodialysis patients: a retrospective single-center cohort study

  Unadjusted Model 1 Model 2
HR (95% CI) p HR (95% CI) p HR (95% CI) p
All-cause mortality
 Q1 1 (Reference) <0.001 1 (Reference) <0.001 1 (Reference) 0.003
 Q2 1.23 (0.52 to 2.93)   0.95 (0.37 to 2.49)   0.71 (0.26 to 1.96)  
 Q3 3.06 (1.43 to 6.52)   2.24 (0.98 to 5.16)   1.94 (0.83 to 4.58)  
 Q4 4.37 (2.10 to 9.10)   4.37 (1.94 to 9.84)   3.12 (1.26 to 7.74)  
  per 104 cells/μL 1.29 (1.18 to 1.42) <0.001 1.37 (1.23 to 1.53) <0.001 1.33 (1.17 to 1.51) <0.001
Cardiovascular mortality
 Q1 1 (Reference) <0.001 1 (Reference) 0.005 1 (Reference) 0.03
 Q2 1.86 (0.56 to 6.19)   1.91 (0.47 to 7.62)   1.59 (0.37 to 6.79)  
 Q3 5.59 (1.92 to 16.27) 4.97 (1.41 to 17.46) 4.18 (1.14 to 15.25)
 Q4 5.67 (1.94 to 16.59) 6.57 (1.85 to 23.34) 4.93 (1.24 to 19.56)
  per 104 cells/μL 1.28 (1.14 to 1.43) <0.001 1.37 (1.19 to 1.56) <0.001 1.38 (1.17 to 1.63) <0.001
  1. Patients were quartiled according to reticulocyte count. Q1, ≤30.1 × 103 cells/μL; Q2, 30.2 to 39.4 × 103 cells/μL; Q3, 39.6 to 53.6 × 103 cells/μL; Q4, ≥53.7 × 103 cells. Model 1 is adjusted for age, sex, diabetic nephropathy, duration of dialysis, interdialysis weight gain, smoking status, vascular disease history, use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, systolic blood pressure, diastolic blood pressure, and weekly dose of recombinant human erythropoietin. Model 2 is adjusted for model 1 covariates and hemoglobin, white blood cell, platelet count, transferrin saturation, ferritin, phosphorus inorganic, creatinine, albumin, and C-reactive protein
  2. Note: HR hazard ratio, CI confidence interval
  3. p for linear trend